Navigation Links
Fate Therapeutics Initiates Phase 2 Clinical Study of ProHema for the Treatment of Hematologic Malignancies
Date:11/27/2012

SAN DIEGO, Nov. 27, 2012 /PRNewswire/ -- Fate Therapeutics, Inc., a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators, announced today the initiation of a randomized, controlled, Phase 2 multi-center study of its investigational hematopoietic stem cell therapy, ProHema, in adult patients undergoing double umbilical cord blood transplantation (dUCBT) for hematologic malignancy.  The advancement of ProHema into later-stage development builds upon positive results from a Phase 1b single-center study, interactions with the U.S. Food and Drug Administration and refinements to the product manufacturing process.  The previously completed Phase 1b study achieved its primary objective of demonstrating safety and tolerability.  The study also established early clinical proof-of-concept – trends of accelerated neutrophil recovery, improved 100-day survival and low rates of graft-versus-host disease were evident, and durable and preferential reconstitution with ProHema occurred in 10 of 12 evaluable patients.  ProHema is produced through a proprietary, two-hour, ex vivo modulation process, which has been shown to significantly activate key biological pathways involved in hematopoietic stem cell homing, proliferation and survival in preclinical models.

"Allogeneic umbilical cord blood transplantation holds great promise as a potentially curative treatment for children and adults with hematologic malignancies and many other life-threatening, non-malignant disorders," said Christian Weyer, M.D., M.A.S., President and Chief Executive Officer of Fate Therapeutics.  "ProHema is being developed with the intent to improve outcomes in patients undergoing cord blood transplantation by facilitating both accelerated engraftment and durable reconstitution using a simple, point-of-care, ex vivo modulation process. The initiation of Phase 2 marks an important milestone for the company and brings us one step closer towards achieving this objective."

The Phase 2 study is expected to enroll at least 45 adult patients undergoing dUCBT for the treatment of hematologic malignancies.  Patients will be randomized, with a ratio of 2:1, to receive either ProHema plus an unmanipulated cord blood unit or two unmanipulated cord blood units.  The study will evaluate time to neutrophil and platelet recovery, incidence of serious infections and graft-versus-host disease, 100-day mortality and relative dominance of ProHema over the unmanipulated cord in contributing to reconstitution.  Results are expected in 2013.

"The preclinical and clinical data obtained to date suggest that ProHema may address several of the unmet medical needs in the evolving field of hematopoietic stem cell transplantation," said Steven Devine, M.D., Professor of Medicine and Program Director of the Blood and Marrow Transplant Program at the Ohio State University and a principal investigator of the Phase 2 clinical study.  "While further investigation is required, an intervention that enables early and durable reconstitution of the best-HLA-matched cord blood unit has the potential to improve patient outcomes and substantially enhance the therapeutic value proposition of cord blood transplant."

About ProHema

ProHema is an innovative cord blood-derived cell therapy containing pharmacologically-modulated hematopoietic stem cells (HSCs).  ProHema is produced through a proprietary, two-hour, ex vivo cell modulation process that results in rapid activation of key biological pathways involved in homing, proliferation and survival of HSCs.  In preclinical testing, ProHema has demonstrated the potential to accelerate engraftment and to drive durable hematopoietic reconstitution, without the need for multi-week expansion protocols.  In an initial Phase 1b study in adult patients with hematologic malignancies undergoing double umbilical cord blood transplant (dUCBT), the median time to neutrophil recovery (> 500 cells/microliter) with ProHema was 17.5 days, which compares favorably to historical norms for patients undergoing dUCBT.  In that study, ProHema provided the dominant source of hematopoiesis in 10 of 12 evaluable subjects, suggesting that treatment with ProHema may accelerate engraftment and drive durable and preferential reconstitution.

About Fate Therapeutics, Inc.

Fate Therapeutics is a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators.  The Company's first clinical program, ProHema, is an innovative cord blood-derived cell therapy containing ex vivo pharmacologically-modulated hematopoietic stem cells and is being developed to improve hematopoietic reconstitution in patients undergoing stem cell transplant.  In addition, Fate Therapeutics has preclinical programs of novel in vivo stem cell modulators for skeletal muscle regeneration and hearing restoration.  To advance its discovery and development efforts, the Company applies its award-winning, proprietary, induced pluripotent stem cell technology to generate rare cell populations and model disease.  Fate Therapeutics is headquartered in San Diego, CA, with a subsidiary in Ottawa, Canada.  For more information, please visit www.fatetherapeutics.com.


'/>"/>
SOURCE Fate Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Epizyme Publishes Current Review on Targeting Protein Methyltransferases for Personalized Cancer Therapeutics
2. MabVax Therapeutics Closes $5.25 Million Financing with Numoda Capital Innovations, Burrill Capital Fund IV, and RTP Venture Fund
3. Cystic Fibrosis Foundation Therapeutics Announces $58 Million CF Drug Discovery Agreement with Pfizer
4. Echo Therapeutics Hires Daniel Sunday as Vice President of Manufacturing and Global Supply Chain
5. Caliber and ImmunGene Launch Valor Biotherapeutics, a Joint Venture to Develop Antibody-Interferon Fusion Therapeutics to Treat Cancers
6. Echo Therapeutics Chosen to Present at the 12th Annual Diabetes Technology Meeting
7. Immunomic Therapeutics Begins Phase I Japanese Red Cedar JRC-LAMP-Vax Vaccine Safety Study
8. Stemline Therapeutics Lead Clinical Candidate SL-401 Induces a Complete Response in a Patient with a Drug-Refractory Plasmacytoid Dendritic Cell Neoplasm
9. Echo Therapeutics Announces Third Quarter 2012 Financial Results
10. Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
11. Particle Sciences Develops Novel Ocular Formulation for Eyeon Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... , May 3, 2016  Specialty Silicone Fabricators ... that shows how a cleanroom works. The free ... about science and technology. ... a technology company, SSF enthusiastically supports the Science, ... educators foster the next generation of innovators. We ...
(Date:5/3/2016)... , May 3, 2016 ... bekannt, dass sie einen entscheidenden Meilenstein durch ... Ein Aufruf zum Handeln, um Patientenresultate  bei ... trägt zu Fortschritten im Verständnis der Hepatischen ... ein Bewusstsein für Hepatische Enzephalopathie in der ...
(Date:5/2/2016)... Mass. , May 2, 2016  While nearly ... that osteoporosis can have on their health, only about ...   according to the results of a new survey ... To mark the start of National Osteoporosis Month, Hologic ... health, which affects nearly 56 million Americans. ...
Breaking Medicine Technology:
(Date:5/4/2016)... ... 04, 2016 , ... With the stamp of approval from the United States ... National Cancer Research Month. According to the American Cancer Society (2016) , this ... one in four Americans dying as a result. , With numbers as influential as ...
(Date:5/4/2016)... ... May 04, 2016 , ... Vasont ... Vasont Universal Integrator (VUI) extension supports the latest release of Adobe FrameMaker, Release ... 2015 interlace the process of creating, editing and storing XML. , ...
(Date:5/3/2016)... ... , ... ProIntro Glitch is a set of 30 self-animating glitch-themed intros created ... to add a terrifying opener to any video or media. Choose from unique styles ... greater contrast, all the user has to do is increase the turn on background ...
(Date:5/3/2016)... ... May 03, 2016 , ... Healing Cancer in This Century is ... move toward recovery and is offered by creator and visionary Carlos Caridad. Healing ... Radio show considering medical and healing modalities of the fields of Integrative, Alternative, ...
(Date:5/3/2016)... ... ... is now open for the 31st annual AIDS Walk Boston & 5K Run , ... Esplanade. The event regularly draws thousands of participants, making it AIDS Action Committee’s largest annual ... by the USA Track & Field Association. , The AIDS Walk & 5K Run ...
Breaking Medicine News(10 mins):